Advanced search
Publication Cover
Journal of Medical Economics Volume 18, 2015 - Issue 6
Submit an article Journal homepage
1,190
Views
12
CrossRef citations to date
0
Altmetric
Review

Cost per remission and cost per response with infliximab, adalimumab, and golimumab for the treatment of moderately-to-severely active ulcerative colitis

Kabirraaj ToorRedwood Outcomes, Vancouver, British Columbia, Canada, and School of Population and Public Health, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
,
Eric DruytsRedwood Outcomes, Vancouver, British Columbia, Canada, and Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
,
Jeroen P. JansenRedwood Outcomes, Vancouver, British Columbia, Canada, and Department of Public Health and Community Medicine, Tufts University, Boston, MA, USA
&
Kristian ThorlundRedwood Outcomes, Vancouver, British Columbia, Canada, Department of Clinical Epidemiology & Biostatistics, McMaster University, Hamilton, Ontario, Canada, and Stanford Prevention Research Center, Stanford University, Stanford, CA, USACorrespondence[email protected]
Pages 437-446 | Accepted 23 Jan 2015, Published online: 18 Feb 2015

References

  • D'Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007;132:763-86
  • Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011;60:780-7
  • Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76
  • Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014;146:96-109.e101
  • Danese S, Fiorino G, Peyrin-Biroulet L, et al. Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. Ann Intern Med 2014;160:704-11
  • Thorlund K, Druyts E, Eapen S, et al. Comparative efficacy and safety of golimumab, infliximab and adalimumab for the treatment of moderate to severe ulcerative colitis: a Bayesian indirect treatment comparison meta-analysis. Montreal, Canada: International Society for Pharmacoeconomics and Outcomes Research, 2014
  • Thorlund K, Druyts E, Mills EJ, et al. Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naive to anti-TNF therapy: An indirect treatment comparison meta-analysis. J Crohn’s Colitis 2014;80:571-81
  • Stidham RW, Lee TC, Higgins PD, et al. Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis. Alimen Pharmacol Therapeut 2014;39:660-71
  • Régie de l'assurance maladie du Québec (RAMQ). Liste de médicaments (no 44). Quebec: Gouvernement due Quebec, 2013
  • Brereton N, Bodger K, Kamm MA, et al. A cost-effectiveness analysis of MMX mesalazine compared with mesalazine in the treatment of mild-to-moderate ulcerative colitis from a UK perspective. J Med Econ 2010;13:148-61
  • Chaudhary MA, Fan T. Cost-effectiveness of infliximab for the treatment of acute exacerbations of ulcerative colitis in the Netherlands. Biol Ther 2013;3:45-60
  • Park KT, Tsai R, Perez F, et al. Cost-effectiveness of early colectomy with ileal pouch-anal anastamosis versus standard medical therapy in severe ulcerative colitis. Ann surg 2012;256:117-24
  • Punekar YS, Hawkins N. Cost-effectiveness of infliximab for the treatment of acute exacerbations of ulcerative colitis. Eur J Health Econ: HEPAC: Health Econ Prevent Care 2010;11:67-76
  • Ung V, Thanh NX, Wong K, et al. Real-life treatment paradigms show infliximab is cost-effective for management of ulcerative colitis. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc 2014;12:1871-8.e1878
  • Lofland JH, Mallow P, Rizzo J. Cost-per-remission analysis of infliximab compared to adalimumab among adults with moderate-to-severe ulcerative colitis. J Med Econ 2013;16:461-7
  • Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012;142:257-65 e251–3
  • Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. New York, NY: Oxford University Press, 2006
  • Aratari A, Papi C, Clemente V, et al. Colectomy rate in acute severe ulcerative colitis in the infliximab era. Digest Liver Dis Off J Italian Soc Gastroenterol Italian Assoc Study Liver 2008;40:821-26
  • Gies N, Kroeker KI, Wong K, et al. Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort. Alimentary Pharmacol Therapeut 2010;32:522-8
  • Kaplan GG, Seow CH, Ghosh S, et al. Decreasing colectomy rates for ulcerative colitis: a population-based time trend study. Am J Gastroenterol 2012;107:1879-87
  • Kim IK, Park KJ, Kang GH, et al. Risk factors for complications after total colectomy in ulcerative colitis. Turk J Gastroenterol Off J Turk Soc Gastroenterol 2012;23:515-22
  • Targownik LE, Singh H, Nugent Z, et al. The epidemiology of colectomy in ulcerative colitis: results from a population-based cohort. Am j gastroenterol 2012;107:1228-35
  • Régie de l’assurance maladie du Québec (RAMQ). Manuel des médecins spécialistes (no 150). 2012

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.